Astrazeneca (AZN) Inventory Average (2009 - 2026)
Astrazeneca (AZN) posted quarterly Inventory Average of $6.8 billion for Q2 2026, up 9.32% year-over-year from $6.2 billion in Q2 2025, and up 2.86% quarter-over-quarter from $6.6 billion in Q1 2026.
Astrazeneca (AZN) Inventory Average (2009 - 2026) Analysis & Trends
Astrazeneca's Inventory Average history runs 18 years deep, the most recent figure standing at $6.8 billion for Q2 2026.
- In Q2 2026, Inventory Average rose 9.32% year-over-year to $6.8 billion; the TTM figure through Jun 2026 stood at $6.8 billion (up 9.32% YoY), while the FY2025 annual figure was $5.9 billion, up 10.58% from the prior year.
- Inventory Average for Q2 2026 stood at $6.8 billion, up from $6.6 billion in the prior quarter.
- The five-year high for Inventory Average was $8.3 billion in Q1 2022, with the low at $4.8 billion in Q1 2023.
- The 5-year median for Inventory Average is $5.6 billion (2022), against an average of $5.9 billion.
- Peak annual rise in Inventory Average reached 156.81% in 2022, while the deepest fall reached 49.89% in 2022.
- Astrazeneca's Inventory Average stood at $4.9 billion in 2022, then grew by 9.6% to $5.4 billion in 2023, then grew by 2.18% to $5.5 billion in 2024, then grew by 20.09% to $6.6 billion in 2025, then advanced by 2.68% to $6.8 billion in 2026.
- Business Quant data shows AZN's Inventory Average at $6.8 billion in Q2 2026, $6.6 billion in Q1 2026, and $6.6 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.31 Bn | 632.55 Bn | 17.26 Bn | 14.86 Bn |
| 2 | AbbVie | 470.15 Bn | 463.58 Bn | 12.70 Bn | 5.09 Bn |
| 3 | Merck | 377.27 Bn | 370.13 Bn | 12.21 Bn | 6.34 Bn |
| 4 | Novartis Ag | 302.88 Bn | 295.19 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.92 Bn | 253.02 Bn | 12.86 Bn | 6.75 Bn |
| 6 | Amgen | 236.83 Bn | 222.84 Bn | 7.24 Bn | 6.20 Bn |
| 7 | Gilead Sciences | 183.08 Bn | 179.90 Bn | 6.22 Bn | 1.93 Bn |
| 8 | Pfizer | 160.37 Bn | 148.67 Bn | 10.94 Bn | 10.31 Bn |
| 9 | Gsk | 106.08 Bn | 101.91 Bn | 8.24 Bn | 8.36 Bn |
| 10 | Sanofi | 55.30 Bn | 47.92 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.75 Bn |
| Mar 31, 2026 | 6.56 Bn |
| Dec 31, 2025 | 6.58 Bn |
| Sep 30, 2025 | 6.53 Bn |
| Jun 30, 2025 | 6.18 Bn |
| Mar 31, 2025 | 5.59 Bn |
| Dec 31, 2024 | 5.48 Bn |
| Sep 30, 2024 | 5.66 Bn |
| Jun 30, 2024 | 5.50 Bn |
| Mar 31, 2024 | 5.38 Bn |
| Dec 31, 2023 | 5.36 Bn |
| Sep 30, 2023 | 5.17 Bn |
| Jun 30, 2023 | 5.01 Bn |
| Mar 31, 2023 | 4.83 Bn |
| Dec 31, 2022 | 4.89 Bn |
| Sep 30, 2022 | 5.65 Bn |
| Jun 30, 2022 | 6.92 Bn |
| Mar 31, 2022 | 8.30 Bn |
| Dec 31, 2021 | 9.76 Bn |
| Sep 30, 2021 | 7.65 Bn |